Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
East Asian Arch Psychiatry ; 30(2): 39-43, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32611825

ABSTRACT

BACKGROUND: The DSM-IV and the DSM-5 eliminated the importance of the syndromal identity of melancholic depression in favour of a dimensional model within the domain of major depressive disorders. Melancholic depression was excluded from DSM as a distinct disorder owing to the impact of ageing, genetics, and course of illness. We challenge these assertions using retrospective data collected from patients with depression. METHOD: Electronic medical records of 1073 patients with depressive-spectrum disorders in 12 centres across Germany spanning from January 2010 to June 2013 were retrospectively reviewed. The diagnosis of melancholia was made using the Hamilton Depression Rating Scale 21 items (HAMD-21). Patients were followed up every 2 weeks and yearly until discharge from inpatient units. The final dataset consisted of 1014 patients; each had received a minimum of two complete observations. RESULTS: At baseline, patients with melancholic depression had higher HAMD-21 score than did patients with non-melancholic depression (32.6 vs 23.13, p < 0.001). At the final visit, patients with melancholic depression responded to treatment more often than did patients with non-melancholic depression (81.3% vs 69.04%, p = 0.0156), whereas the two groups were comparable in terms of remission status (50.55 vs 48.68%, p = 0.1943). The relapse rate was higher in patients with melancholic depression than in patients with non-melancholic depression after 1 year (60% vs 45.01%, p = 0.0599), 2 years (77.78% vs 60.36%, p = 0.0233), and 4 years (80% vs 64.45%, p = 0.0452). CONCLUSION: Melancholic depression has an identifiable constellation of symptoms and it is not just a severe form of major depression. Melancholic depression is not the result of age-related or pathoplastic changes. We advocate including melancholia as its own illness entity in the next edition of the DSM.


Subject(s)
Depressive Disorder, Major/diagnosis , Depressive Disorder/diagnosis , Adult , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , Inpatients , Male , Middle Aged , Psychiatric Status Rating Scales/statistics & numerical data , Recurrence , Remission Induction , Retrospective Studies , Time Factors
2.
Eur Psychiatry ; 30(2): 228-32, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25555342

ABSTRACT

BACKGROUND: Affective disorders are associated with an increased risk of cardiovascular disease, which, at least partly, appears to be independent of psychopharmacological treatments used to manage these disorders. Reduced heart rate variability (SDNN) and a low Omega-3 Index have been shown to be associated with increased risk for death after myocardial infarction. Therefore, we set out to investigate heart rate variability and the Omega-3 Index in euthymic patients with bipolar disorders. METHODS: We assessed heart rate variability (SDNN) and the Omega-3 Index in 90 euthymic, mostly medicated patients with bipolar disorders (Bipolar-I, Bipolar-II) on stable psychotropic medication, free of significant medical comorbidity and in 62 healthy controls. Heart rate variability was measured from electrocardiography under a standardized 30 minutes resting state condition. Age, sex, BMI, smoking, alcohol consumption and caffeine consumption as potential confounders were also assessed. RESULTS: Heart rate variability (SDNN) was significantly lower in patients with bipolar disorders compared to healthy controls (35.4 msec versus 60.7 msec; P<0.0001), whereas the Omega-3 Index did not differ significantly between the groups (5.2% versus 5.3%). In a linear regression model, only group membership (patients with bipolar disorders versus healthy controls) and age significantly predicted heart rate variability (SDNN). CONCLUSION: Heart rate variability (SDNN) may provide a useful tool to study the impact of interventions aimed at reducing the increased risk of cardiovascular disease in euthymic patients with bipolar disorders. The difference in SDNN between cases and controls cannot be explained by a difference in the Omega-3 Index.


Subject(s)
Bipolar Disorder/physiopathology , Fatty Acids, Omega-3/blood , Heart Rate/physiology , Adult , Aged , Bipolar Disorder/blood , Electrocardiography , Female , Humans , Male , Middle Aged
3.
Neurobiol Aging ; 27(8): 1051-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16169126

ABSTRACT

Clinical utility of magnetic resonance imaging (MRI) for the diagnosis and assessment of neurodegenerative diseases may depend upon the reliability of MRI measurements, especially when applied within a multicenter context. In the present study, we assessed the reliability of MRI through a phantom test at a total of eleven clinics. Performance and entry criteria were defined liberally in order to support generalizability of the results. For manual hippocampal volumetry, automatic segmentation of brain compartments and voxel-based morphometry, multicenter variability was assessed on the basis of MRIs of a single subject scanned at ten of the eleven sites. In addition, cranial MRI scans obtained from 73 patients with Alzheimer's disease (AD) and 76 patients with mild cognitive impairment were collected at subset of six centers to assess differences in grey matter volume. Results show that nine out of eleven centers tested met the reliability criteria of the phantom test, where two centers showed aberrations in spatial resolution, slice thickness and slice position. The coefficient of variation was 3.55% for hippocampus volumetry, 5.02% for grey matter, 4.87% for white matter and 4.66% for cerebrospinal fluid (CSF). The coefficient of variation was 12.81% (S.D.=9.06) for the voxel intensities within grey matter and 8.19% (S.D.=6.9) within white matter. Power analysis for the detection of a difference in the volumes of grey matter between AD and MCI patients across centers (d=0.42) showed that the total sample size needed is N=180. In conclusion, despite minimal inclusion criteria, the reliability of MRI across centers was relatively good.


Subject(s)
Alzheimer Disease/diagnosis , Brain/pathology , Cognition Disorders/diagnosis , Imaging, Three-Dimensional/methods , Magnetic Resonance Imaging/methods , Adult , Female , Germany , Humans , Male , Netherlands , Phantoms, Imaging , Reproducibility of Results , Sensitivity and Specificity
4.
Dement Geriatr Cogn Disord ; 20(6): 352-7, 2005.
Article in English | MEDLINE | ID: mdl-16192725

ABSTRACT

BACKGROUND: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucose metabolism using positron emission tomography (PET). OBJECTIVE: We hypothesized that neuronal activation as measured by PET is a more sensitive index of neuronal dysfunction than activity during rest. We investigated if the correlations between dementia severity as measured with the Mini Mental State Examination (MMSE) and glucose metabolism are an artifact of brain atrophy. METHOD: Glucose metabolism was measured using [18F]fluorodeoxyglucose PET during rest and activation due to audiovisual stimulation in 13 mild to moderate AD patients (MMSE score > or = 17). PET data were corrected for brain atrophy. RESULTS: In the rest condition, glucose metabolism was correlated with the MMSE score primarily within the posterior cingulate and parietal lobes. For the activation condition, additional correlations were within the primary and association audiovisual areas. Most local maxima remained significant after correcting for brain atrophy. CONCLUSION: PET activity measured during audiovisual stimulation was more sensitive to functional alterations in glucose metabolism in AD patients compared to the resting PET. The association between glucose metabolism and MMSE score was not dependent on brain atrophy.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Cerebral Cortex/metabolism , Cognition/physiology , Glucose/metabolism , Aged , Alzheimer Disease/diagnostic imaging , Atrophy/diagnostic imaging , Brain/pathology , Female , Fluorodeoxyglucose F18 , Humans , Male , Mental Status Schedule , Middle Aged , Positron-Emission Tomography
5.
Neurology ; 59(4): 627-9, 2002 Aug 27.
Article in English | MEDLINE | ID: mdl-12196665

ABSTRACT

In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau(231)) in CSF correlate with progression of cognitive decline. High CSF p-tau(231) levels at baseline, but not total tau protein levels, correlated with cognitive decline and conversion from MCI to AD. Independently, old age and APOE-epsilon 4 carrier status were predictive as well. Our data indicate that an increased p-tau(231) level is a potential risk factor for cognitive decline in patients with MCI.


Subject(s)
Cognition Disorders/cerebrospinal fluid , Cognition Disorders/diagnosis , tau Proteins/cerebrospinal fluid , tau Proteins/metabolism , Adult , Age Factors , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/complications , Alzheimer Disease/diagnosis , Apolipoprotein E4 , Apolipoproteins E/genetics , Biomarkers/cerebrospinal fluid , Cognition Disorders/complications , Cognition Disorders/genetics , Disease Progression , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged , Neuropsychological Tests , Phosphorylation , Predictive Value of Tests , Regression Analysis , Risk Factors , Threonine/metabolism
6.
J Neurol Sci ; 194(1): 35-40, 2002 Feb 15.
Article in English | MEDLINE | ID: mdl-11809164

ABSTRACT

BACKGROUND: Neurodegenerative and cerebrovascular diseases show a distinct distribution of regional atrophy and subcortical lesions. OBJECTIVE: To develop an easily applicable landmark-based method for segmentation of the brain into the four cerebral lobes from MRI images. METHOD: The segmentation method relies on a combination of anatomical landmarks and geometrical definitions. It is applied on the surface reconstruction of the MRI volume. The internal borders between the lobes are defined on the axial slices of the brain. The reliability of this method was determined from MRI scans of 10 subjects. To illustrate the use of the method, it was applied to MRI scans of an independent group of 10 healthy elderly subjects and 10 patients with vascular dementia to determine the regional distribution of white matter hyperintensities (WMH). RESULTS: The intra-rater relative error (and intra-class correlation coefficient) of the lobe segmentation ranged from 1.6% to 6.9% (from 0.91 to 0.99). The inter-rater relative error (and intra-class correlation coefficient) ranged from 1.4% to 5.2% (from 0.96 to 0.99). Density of WMH was significantly higher in all four lobes in VD patients compared to controls (p<0.05). Within each group, WMH density was significantly higher in frontal and parietal than in temporal and occipital lobes (p<0.05). CONCLUSION: This landmark based method can accommodate age and disease-related changes in brain morphology. It may be particularly useful for the study of neurodegenerative and cerebrovascular disease and for the validation of template-based automated techniques.


Subject(s)
Alzheimer Disease/diagnosis , Brain , Dementia, Vascular/diagnosis , Image Enhancement/methods , Magnetic Resonance Imaging/methods , Aged , Alzheimer Disease/pathology , Brain/anatomy & histology , Brain/pathology , Dementia, Vascular/pathology , Frontal Lobe/anatomy & histology , Frontal Lobe/pathology , Humans , Observer Variation , Occipital Lobe/anatomy & histology , Occipital Lobe/pathology , Parietal Lobe/anatomy & histology , Parietal Lobe/pathology , Pilot Projects , Predictive Value of Tests , Reproducibility of Results , Temporal Lobe/anatomy & histology , Temporal Lobe/pathology
7.
Psychiatr Genet ; 11(3): 169-72, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11702061

ABSTRACT

A 44 base pair deletion/insertion polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR) was examined in 124 German suicide attempters, who were consecutively hospitalized, and 185 German normal control subjects without a history of any DSM-IV axis I or II mental disorder. Both patients and control subjects were recruited from the same geographic area. There was no significant difference in allele or genotype frequency between patients and control subjects. There were also no differences when the patients were divided into several subgroups (suicide attempters with a violent method, and suicide attempters with a lifetime history of mood disorders, unipolar depression, personality disorders). These results suggest that the 5-HTTLPR polymorphism is unlikely to play a major role in the genetic susceptibility to suicide attempts. Conflicting results among the present and previous studies regarding an association between the polymorphism and suicidal behavior, however, suggest the possibility that there may be unidentified specific subtypes of suicidal behavior that are significantly associated with the polymorphism or, alternatively, simply reflect false-positive association results.


Subject(s)
Carrier Proteins/genetics , Membrane Glycoproteins/genetics , Membrane Transport Proteins , Nerve Tissue Proteins , Polymorphism, Genetic , Promoter Regions, Genetic , Suicide, Attempted , Depressive Disorder/genetics , Gene Frequency , Genotype , Humans , Mood Disorders/genetics , Personality Disorders/genetics , Reference Values , Serotonin Plasma Membrane Transport Proteins
8.
Neurology ; 57(5): 801-5, 2001 Sep 11.
Article in English | MEDLINE | ID: mdl-11552007

ABSTRACT

OBJECTIVE: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-beta-amyloid (Abeta) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. BACKGROUND: Immunization with preaggregated amyloid beta-peptide (Abeta(1-42)) and administration of antibodies against Abeta into amyloid precursor protein APP(V717F)- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Abeta clearance from brain. METHODS: A sensitive ELISA was performed to detect levels of naturally occurring anti-Abeta antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Abeta antibodies also exist in the human blood. RESULT: - Naturally occurring antibodies directed against Abeta were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Abeta antibody titers are significantly lower in patients with AD compared with healthy control subjects. CONCLUSION: Naturally occurring antibodies directed against Abeta exist in human CSF and plasma. The CSF anti-Abeta antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.


Subject(s)
Alzheimer Disease/immunology , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Peptides/immunology , Antibodies/cerebrospinal fluid , Aged , Alzheimer Disease/blood , Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/blood , Amyloid beta-Protein Precursor/blood , Amyloid beta-Protein Precursor/cerebrospinal fluid , Analysis of Variance , Animals , Antibodies/blood , Enzyme-Linked Immunosorbent Assay , Humans , Mice , Middle Aged
9.
Ann Neurol ; 50(2): 150-6, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11506396

ABSTRACT

We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non-AD-demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho-tau199) by a recently established sandwich ELISA. The CSF/phospho-tau199 levels in the AD group were significantly elevated compared to those in all the other non-AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group vs all the other non-AD groups using the CSF/phospho-tau199 were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho-tau199 and CSF/total-tau levels in the AD group. Elevated CSF/phospho-tau199 in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho-tau199 may be a novel and logical biomarker in supporting antemortem diagnosis of AD.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/genetics , Apolipoproteins E/genetics , Biomarkers/cerebrospinal fluid , Serine/genetics , tau Proteins/cerebrospinal fluid , Aged , Aged, 80 and over , Apolipoprotein E4 , Enzyme-Linked Immunosorbent Assay , Female , Genotype , Humans , Male , Middle Aged , Phosphorylation , ROC Curve , Reproducibility of Results , Sex Factors
12.
Psychopathology ; 17(2): 98-104, 1984.
Article in English | MEDLINE | ID: mdl-6729005

ABSTRACT

Different diagnostic groups were compared in order to find out how constant individual patterns of illness remained over different hospital admissions. First, each of the syndrome scales in the Inpatient Multidimensional Psychiatric Scale and the Clinical Self-Rating Scales was examined to see how stable the patients' scores remained over two different admissions. Low correlations between scores on the two admissions were seen in the scales for mania and depression, reflecting changes in the clinical symptom patterns of patients with affective disorders. Many other scales, however, were fairly stable and were more closely connected with the given diagnosis. Secondly, each patient's pattern of illness on the first admission was compared with his or her pattern on the second admission. It was observed that patients with diagnoses of schizophrenia or schizo-affective psychosis tended to have less stable patterns of illness.


Subject(s)
Hospitalization , Mental Disorders/diagnosis , Affective Disorders, Psychotic/diagnosis , Humans , Mental Disorders/psychology , Mental Disorders/therapy , Neurotic Disorders/diagnosis , Psychiatric Status Rating Scales , Psychometrics , Psychopathology , Psychotic Disorders/diagnosis , Recurrence , Schizophrenia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...